Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Prostate Cancer

  Free Subscription


27.01.2020

2 AJR Am J Roentgenol
1 Am J Clin Oncol
4 BJU Int
1 BMC Cancer
2 Br J Radiol
1 Clin Cancer Res
1 Eur Urol
1 J Magn Reson Imaging
7 J Urol
4 Nat Rev Urol
1 PLoS Comput Biol
8 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. ABREU-GOMEZ J, Krishna S, Narayanasamy S, Flood TA, et al
    Dynamic Contrast-Enhanced MRI-Upgraded Prostate ImagingReporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
    AJR Am J Roentgenol. 2019 May 23:1-8. doi: 10.2214/AJR.18.21005.
    PubMed     Text format     Abstract available

  2. ABREU-GOMEZ J, Shabana W, McInnes MDF, O'Sullivan JP, et al
    Regional Standardization of Prostate Multiparametric MRI Performance and Reporting: Is There a Role for a Director of Prostate Imaging?
    AJR Am J Roentgenol. 2019 Jun 10:1-7. doi: 10.2214/AJR.19.21111.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  3. LIU Z, Zhang T, Ma Z, Zheng S, et al
    Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
    Am J Clin Oncol. 2020 Jan 17. doi: 10.1097/COC.0000000000000660.
    PubMed     Text format     Abstract available


    BJU Int

  4. LOVEGROVE CE, Peters M, Guillaumier S, Arya M, et al
    Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15004.
    PubMed     Text format     Abstract available

  5. VIKTORIN P, Putora PM, Schmid HP, Plasswilm L, et al
    Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry.
    BJU Int. 2020 Jan 21. doi: 10.1111/bju.15003.
    PubMed     Text format     Abstract available

  6. AMIN A, Blazevski A, Thompson J, Scheltema MJ, et al
    PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prost
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.14999.
    PubMed     Text format     Abstract available

  7. BRATT O, Drevin L, Prutz KG, Carlsson S, et al
    Prostate cancer in kidney transplant recipients- a nationwide register study.
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.15002.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Text format     Abstract available


    Br J Radiol

  9. SUSHENTSEV N, Caglic I, Sala E, Shaida N, et al
    The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload.
    Br J Radiol. 2020 Jan 23:20190929. doi: 10.1259/bjr.20190929.
    PubMed     Text format     Abstract available

  10. DEANTONI CL, Fodor A, Cozzarini C, Fiorino C, et al
    Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.
    Br J Radiol. 2020 Jan 23:20190353. doi: 10.1259/bjr.20190353.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  11. FAISAL FA, Murali S, Kaur H, Vidotto T, et al
    CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-1669.
    PubMed     Text format     Abstract available


    Eur Urol

  12. HUNT TC, O'Neil BB
    Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening.
    Eur Urol. 2020 Jan 17. pii: S0302-2838(20)30001.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  13. HECTORS SJ, Said D, Gnerre J, Tewari A, et al
    Luminal Water Imaging: Comparison With Diffusion-Weighted Imaging (DWI) and PI-RADS for Characterization of Prostate Cancer Aggressiveness.
    J Magn Reson Imaging. 2020 Jan 21. doi: 10.1002/jmri.27050.
    PubMed     Text format     Abstract available


    J Urol

  14. PREISSER F, van den Bergh RCN, Gandaglia G, Ost P, et al
    Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;203:338-343.
    PubMed     Text format     Abstract available

  15. DENIFFEL D, Zhang Y, Salinas E, Satkunasivam R, et al
    Reducing Unnecessary Prostate Multiparametric Magnetic Resonance Imaging by Using Clinical Parameters to Predict Negative and Indeterminate Findings.
    J Urol. 2020;203:292-298.
    PubMed     Text format     Abstract available

  16. WATSON V, McCartan N, Krucien N, Abu V, et al
    Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study.
    J Urol. 2020 Jan 22:101097JU0000000000000754. doi: 10.1097/JU.0000000000000754.
    PubMed     Text format     Abstract available

  17. HANEY NM, Faisal FA, Lu J, Guedes LB, et al
    PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy.
    J Urol. 2020;203:344-350.
    PubMed     Text format     Abstract available

  18. ABEDALI ZA, Calaway AC, Large T, Lingeman JE, et al
    The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate.
    J Urol. 2020;203:304-310.
    PubMed     Text format     Abstract available

  19. ERICSON KJ, Wu SS, Lundy SD, Thomas LJ, et al
    Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    J Urol. 2020;203:311-319.
    PubMed     Text format     Abstract available

  20. ZHAO H, Howard LE, De Hoedt A, Terris MK, et al
    Racial Discrepancies in Overall Survival among Men Treated with (223)Radium.
    J Urol. 2020;203:331-337.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  21. THOMA C
    AR activity in treatment-naive prostate tumours.
    Nat Rev Urol. 2019;16:640.
    PubMed     Text format    

  22. STONE L
    UT-34: a promising new AR degrader.
    Nat Rev Urol. 2019;16:640.
    PubMed     Text format    

  23. FENNER A
    Germline-epigenome crosstalk promotes aggressive subsets of prostate tumours.
    Nat Rev Urol. 2019;16:693.
    PubMed     Text format    

  24. THOMA C
    Clinical decision-making with AR-V7.
    Nat Rev Urol. 2019;16:694.
    PubMed     Text format    


    PLoS Comput Biol

  25. JI Z, Zhao W, Lin HK, Zhou X, et al
    Systematically understanding the immunity leading to CRPC progression.
    PLoS Comput Biol. 2019;15:e1007344.
    PubMed     Text format     Abstract available


    Prostate

  26. LI X, Huang H, Zhang J, Jiang F, et al
    A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Prostate. 2020 Jan 21. doi: 10.1002/pros.23952.
    PubMed     Text format     Abstract available

  27. MARKOWSKI MC, Shenderov E, Eisenberger MA, Kachhap S, et al
    Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23955.
    PubMed     Text format     Abstract available

  28. XING Z, Li S, Liu Z, Zhang C, et al
    CTCF-induced upregulation of HOXA11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23953.
    PubMed     Text format     Abstract available

  29. WENJING H, Shao Y, Yu Y, Huang W, et al
    Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
    Prostate. 2020 Jan 22. doi: 10.1002/pros.23951.
    PubMed     Text format     Abstract available

  30. PEIFFER LB, Poynton SL, Ernst SE, Hicks JL, et al
    Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis.
    Prostate. 2019;79:1316-1325.
    PubMed     Text format     Abstract available

  31. DONG F, Yang P, Wang R, Sun W, et al
    Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
    Prostate. 2019;79:1284-1293.
    PubMed     Text format     Abstract available

  32. YANG J, Broman MM, Cooper PO, Lanman NA, et al
    Distinct expression patterns of SULT2B1b in human prostate epithelium.
    Prostate. 2019;79:1256-1266.
    PubMed     Text format     Abstract available

  33. SHAH RB, Shore KT, Yoon J, Mendrinos S, et al
    PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Prostate. 2019;79:1267-1273.
    PubMed     Text format     Abstract available


    Urology

  34. HUANG MM, Macura KJ, Landis P, Epstein JI, et al
    Evaluation of apparent diffusion coefficient as a predictor of grade reclassification in men on active surveillance for prostate cancer.
    Urology. 2020 Jan 15. pii: S0090-4295(20)30018.
    PubMed     Text format     Abstract available

  35. AL HUSSEIN AL AWAMLH B, Ma X, Scherr D, Hu JC, et al
    Temporal Changes in Demographic and Clinical Characteristics of Men With Prostate Cancer Electing for Conservative Management in the United States.
    Urology. 2020 Jan 13. pii: S0090-4295(19)31106.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: